You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
As they say: ‘two heads are better than one’ and taking an integrated approach to late phase partnerships can unlock the value of your product for stakeholders. Maximize drug potential through strategy, evidence and clear communication.
Partnering with an experienced CRO is particularly beneficial in late phase clinical research as commercialization and reimbursement data requirements will have been considered from the offset. By outsourcing strategy, clinical trials benefit from a range of expert minds and a committed study partner that will spearhead market access.
An integrated approach helps:
• Identify data needed
• Access realization
• Data generation
• Communications strategy
• Communications execution
Defensive development strategies for cancer drugs can help manage the substantial and increasing commercial risk in…